Oragenics Inc (OGEN) 0.95 $OGEN
Oragenics, Inc. Selects Merriman Capital as Capital Markets Advisor
Thomson Reuters ONE - Thu Sep 18, 8:00AM CDT
SAN FRANCISCO - September 18, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), is pleased to announce that it has been selected as Capital Markets Advisor to Oragenics, Inc. (OGEN).
OGEN: 0.95 (unch)
Oragenics Appoints Key Hires to Drive Lantibiotic Platform Growth and Expansion
Business Wire - Wed Sep 10, 6:45AM CDT
Oragenics, Inc. (NYSE: OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced two new appointments to the Product Development team. Joining the company are Guojun (Shawn) Nie Ph.D., as Director of Process Development, and Mr. Joel Ngoje as Senior Process Scientist. Together, the two bring almost 40 years of pharmaceutical, protein and process development experience to the company. Encouraging progress from the development of Oragenics' novel Lantibiotic platform has necessitated the accelerated expansion of the R & D team to position the pipeline for clinical success.
XON: 20.62 (+2.14), OGEN: 0.95 (unch)
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGEN)
WorldStockWire - Thu Sep 05, 4:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OGEN: 0.95 (unch)
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGENI)
WorldStockWire - Thu Sep 05, 4:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OGEN: 0.95 (unch)
Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Business Wire - Mon Aug 26, 6:45AM CDT
Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE:XON), a synthetic biology company, preliminary experiments demonstrate that a genetically-modified (GM) host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.
XON: 20.62 (+2.14), OGEN: 0.95 (unch)
Intrexon IPO Prices High After Upsizing; Stock Soars
at Investor's Business Daily - Thu Aug 08, 11:28AM CDT
Synthetic-biology startup Intrexon (XON) soared more than 40% on the stock market Thursday after pricing its fattened IPO at the high end of its range. Intrexon priced 10 million shares at $16 apiece to raise $160 million, after last month announcing...
SYN: 1.77 (+0.04), ZIOP: 2.80 (+0.22), FCSC: 2.96 (-0.10), XON: 20.62 (+2.14), OGEN: 0.95 (unch)
Enterococcus Faecium Infections - Pipeline Review, H2 2012
M2 - Thu Aug 01, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k929nz/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. I also provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Enterococcus Faecium Infections Overview Therapeutics Development An Overview of Pipeline Products for Enterococcus Faecium Infections Companies Involved in Enterococcus Faecium Infections Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Aquapharm Biodiscovery Limited - Ceragenix Pharmaceuticals - Immtech Pharmaceuticals - Lorus Therapeutics - MerLion Pharmaceuticals - MicuRx Pharmaceuticals, Inc - Nabi Biopharmaceuticals - Oragenics, Inc - Paratek Pharmaceuticals - Piramal Healthcare Limited - Trius Therapeutics, Inc - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/k9...terococcus
OGEN: 0.95 (unch)
Oragenics to Join the Russell Microcap(R) Index
Business Wire - Tue Jun 25, 8:31AM CDT
Oragenics, Inc. (NYSE MKT:OGEN), a healthcare company focused on becoming the world leader in novel antibiotics against infectious disease and probiotcs for oral health, announced today that it will be included in the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 28, 2013, according to a preliminary list of additions posted June 21st on www.russell.com/indexes.
OGEN: 0.95 (unch)
Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development
TTPH: 23.93 (+0.52), EBS: 21.60 (+0.29), PIP: 1.77 (+0.03), IBIO: 1.63 (-0.14), OGEN: 0.95 (unch), ARDM: 8.30 (+0.17)
Oragenics Launches New Professional and Consumer Commercial Websites
Business Wire - Thu May 02, 9:50AM CDT
Oragenics, Inc. (NYSE:MKT - OGEN) today announced that it has launched two new websites. The first, www.evorapro.com, is designed to educate dental professionals about the benefits of oral probiotics in maintaining good oral health and balance, while also providing information on becoming a partner with Oragenics and offering its professional strength product, EvoraPro, in their practices.
OGEN: 0.95 (unch)
Oragenics To Present Oral Care Probiotics Seminar at SupplySide MarketPlace 2013
Business Wire - Tue Apr 30, 8:33AM CDT
Oragenics, Inc. (NYSE:MKT: OGEN) today announced that Dr. Martin Handfield, Vice President of R&D for Oragenics, will be presenting a seminar entitled "Oral Care Probiotics Development" on Tuesday, April 30th at 5:00 pm at the SupplySide MarketPlace 2013, taking place from April 30 - May 2 at the Jacob Javits Center in New York, NY. SupplySide MarketPlace 2013 brings together the buyers and sellers that drive the dietary supplement, food, beverage, personal care, cosmetic and animal nutrition marketplaces. The Oragenics seminar is part of a practical short course entitled "Pre- & Probiotics Americas 2013: Pre- & Probiotics - Market, Science, Regulations and Applications" and will focus on describing the fundamental basis of oral probiotics, as well as highlighting the competitive advantage of the Oragenics line of oral care products.
OGEN: 0.95 (unch)
Clostridium Infections - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:16AM CDT
Research and Markets has announced the addition of the "Clostridium Infections - Pipeline Review, H1 2013" (http://www.researchandmarkets.com/research/p9lxmj/clostridium) report to their offering. 'Clostridium Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Clostridium Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by u
EBS: 21.60 (+0.29), CBST: 72.42 (+3.27), MRK: 56.63 (+1.12), SRNE: 4.02 (+0.01), OGEN: 0.95 (unch), NVS: 89.24 (+1.04)
Oragenics Announces Approval of Common Stock Listing on NYSE MKT
Business Wire - Mon Apr 08, 9:11AM CDT
Oragenics, Inc. (OTCBB: OGEN) (the "Company" announced today that its common stock has been approved for listing on the NYSE Euronext's NYSE MKT. Trading is expected to commence on the NYSE MKT on Wednesday, April 10, 2013 under the ticker symbol 'OGEN'.
OGEN: 0.95 (unch)
Oragenics Receives First European Patent for ProBiora3(R) Probiotic Blend
Business Wire - Tue Mar 12, 8:23AM CDT
Oragenics, Inc. (OTCQB: OGEN)(OTCBB: OGEN) today announced it has received its first patent approval in Europe for its ProBiora3(R) products. The approval provides additional protection for ProBiora3's proprietary blend of three probiotic bacteria, specifically designed to enhance oral health, whiten teeth and freshen breath. ProBiora3 is currently being sold under the brand name Evora in the U.S. and in over 13 countries around the world.
OGEN: 0.95 (unch)
Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
Business Wire - Tue Feb 12, 7:15AM CST
Oragenics, Inc. (OTCBB: OGEN) announced today that its Exclusive Channel Collaboration (ECC) with Intrexon Corporation, a synthetic biology company, has produced an exponential increase in the fermentation titer of the target compound MU1140 and the discovery of a promising new purification process for this product. This demonstrates significant progress toward the commercial production of its lead lantibiotic, MU1140, and delivers an important step in validating the lantibiotics platform targeting infectious diseases. Oragenics and Intrexon have been working together through the ECC to produce a pipeline of new lantibiotics that have been shown to be active against essentially all Gram-positive pathogens, including vancomycin-resistant enterococci (VRE), Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), as well as multi-drug resistant strains of Mycobacterium tuberculosis.
OGEN: 0.95 (unch)
Oragenics Receives European Union CPNP Notifications for ProBiora3(R) Cosmetic Tablets
Business Wire - Mon Feb 11, 8:00AM CST
Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN), today announced its ProBiora3(R) tablets intended to freshen breath, whiten teeth and contribute to overall oral health has successfully completed an independent third party review of its Cosmetic Product Safety Report. ProBiora3(R) is Oragenics' proprietary blend of probiotics specifically designed for oral care, and is now formulated as a cosmetic mouthwash tablet for use in the European Union. All Oragenics' independent distributors can now distribute the ProBiora3(R) tablets in the EU under a Cosmetic designation.
OGEN: 0.95 (unch)
Oragenics CEO To Present at The BIO CEO & Investor Conference on February 12th 2013
Business Wire - Mon Feb 11, 7:50AM CST
Oragenics, Inc. (OTCQB:OGEN) (OTCBB: OGEN), today announced Dr. John N. Bonfiglio, President and CEO of Oragenics, Inc., will present an overview of the company and an update on activities at the BIO CEO & Investor Conference in New York City on Tuesday, February 12th at 1:15 pm EST. The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies.
OGEN: 0.95 (unch)
Oragenics Inc signs new strategic partnership with Organic Wave Inc, getting access to Japanese pet market
M2 - Wed Jan 23, 10:20AM CST
Oral care probiotics company Oragenics Inc (OTC BB :OGEN) revealed on Tuesday the execution of a new strategic distribution agreement with Organic Wave Inc.
OGEN: 0.95 (unch)
Oragenics Announces New Strategic Partnership with Japanese-Based Company, Organic Wave, Inc. dba KYB America
Business Wire - Tue Jan 22, 7:15AM CST
Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN) (the "Company" , a world leader in oral care probiotics, today announced that the Company has entered into a new three year contract agreement with Organic Wave, Inc. Under the terms of the agreement, Organic Wave will be the exclusive distributor of Oragenics' oral care probiotics for pets in Japan under the Evora name as well as a private label brand. The pet product will contain ProBiora3(R); Oragenics' patented proprietary blend of three probiotics specifically designed for improved oral health.
OGEN: 0.95 (unch)
Oragenics CEO To Present at 6th Annual OneMedForum Investor Conference
Business Wire - Mon Jan 07, 7:15AM CST
Oragenics, Inc. (OTCQB:OGEN) (OTCBB:OGEN), today announced Dr. John Bonfiglio, President and CEO of Oragenics, Inc., will present an overview of the company at the 6th Annual OneMedForum in San Francisco on Tuesday, January 8th at 12:00 pm PST. Launched in 2008 by OneMedPlace, OneMedForum runs concurrently with the 31st Annual J.P. Morgan Healthcare Conference and brings together leading investors, strategic partners and management of some of the most promising emerging life science companies in Asia and North America.
JPM: 58.06 (+0.61), OGEN: 0.95 (unch)
Oragenics, Inc. Selects Merriman Capital as Capital Markets Advisor
Thomson Reuters ONE - Thu Sep 18, 8:00AM CDT
SAN FRANCISCO - September 18, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), is pleased to announce that it has been selected as Capital Markets Advisor to Oragenics, Inc. (OGEN). OGEN: 0.95 (unch)
Oragenics Appoints Key Hires to Drive Lantibiotic Platform Growth and Expansion
Business Wire - Wed Sep 10, 6:45AM CDT
Oragenics, Inc. (NYSE: OGEN), a leader in the development of novel, effective antibiotics and oral care probiotics, today announced two new appointments to the Product Development team. Joining the company are Guojun (Shawn) Nie Ph.D., as Director of Process Development, and Mr. Joel Ngoje as Senior Process Scientist. Together, the two bring almost 40 years of pharmaceutical, protein and process development experience to the company. Encouraging progress from the development of Oragenics' novel Lantibiotic platform has necessitated the accelerated expansion of the R & D team to position the pipeline for clinical success.
XON: 20.62 (+2.14), OGEN: 0.95 (unch)
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGEN)
WorldStockWire - Thu Sep 05, 4:30PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OGEN: 0.95 (unch)
OTC Daily Alert Stock Watch - Oragenics, Inc. (NYSE: OGENI)
WorldStockWire - Thu Sep 05, 4:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
OGEN: 0.95 (unch)
Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project
Business Wire - Mon Aug 26, 6:45AM CDT
Oragenics, Inc. (NYSE MKT: OGEN) announced today that through its Exclusive Channel Collaboration (ECC) with Intrexon Corporation (NYSE:XON), a synthetic biology company, preliminary experiments demonstrate that a genetically-modified (GM) host can be engineered to produce improved titers of OGEN's lead compound MU1140, progressing towards the commercial production of lantibiotics, a novel-class of broad-spectrum antibiotics.
XON: 20.62 (+2.14), OGEN: 0.95 (unch)
Intrexon IPO Prices High After Upsizing; Stock Soars
at Investor's Business Daily - Thu Aug 08, 11:28AM CDT
Synthetic-biology startup Intrexon (XON) soared more than 40% on the stock market Thursday after pricing its fattened IPO at the high end of its range. Intrexon priced 10 million shares at $16 apiece to raise $160 million, after last month announcing...
SYN: 1.77 (+0.04), ZIOP: 2.80 (+0.22), FCSC: 2.96 (-0.10), XON: 20.62 (+2.14), OGEN: 0.95 (unch)
Enterococcus Faecium Infections - Pipeline Review, H2 2012
M2 - Thu Aug 01, 6:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/k929nz/enterococcus) has announced the addition of the "Enterococcus Faecium Infections - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Enterococcus Faecium Infections therapeutic pipeline. I also provides information on the therapeutic development for Enterococcus Faecium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterococcus Faecium Infections. The information is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Enterococcus Faecium Infections. - A review of the Enterococcus Faecium Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Enterococcus Faecium Infections pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Enterococcus Faecium Infections Overview Therapeutics Development An Overview of Pipeline Products for Enterococcus Faecium Infections Companies Involved in Enterococcus Faecium Infections Therapeutics Development Drug Profiles with Product Descriptions and Mechanisms of Action Featured News & Press Releases Appendix Companies Mentioned: - Aquapharm Biodiscovery Limited - Ceragenix Pharmaceuticals - Immtech Pharmaceuticals - Lorus Therapeutics - MerLion Pharmaceuticals - MicuRx Pharmaceuticals, Inc - Nabi Biopharmaceuticals - Oragenics, Inc - Paratek Pharmaceuticals - Piramal Healthcare Limited - Trius Therapeutics, Inc - Wockhardt Limited For more information visit http://www.researchandmarkets.com/research/k9...terococcus
OGEN: 0.95 (unch)
Oragenics to Join the Russell Microcap(R) Index
Business Wire - Tue Jun 25, 8:31AM CDT
Oragenics, Inc. (NYSE MKT:OGEN), a healthcare company focused on becoming the world leader in novel antibiotics against infectious disease and probiotcs for oral health, announced today that it will be included in the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on Friday, June 28, 2013, according to a preliminary list of additions posted June 21st on www.russell.com/indexes.
OGEN: 0.95 (unch)
Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development
TTPH: 23.93 (+0.52), EBS: 21.60 (+0.29), PIP: 1.77 (+0.03), IBIO: 1.63 (-0.14), OGEN: 0.95 (unch), ARDM: 8.30 (+0.17)
Oragenics Launches New Professional and Consumer Commercial Websites
Business Wire - Thu May 02, 9:50AM CDT
Oragenics, Inc. (NYSE:MKT - OGEN) today announced that it has launched two new websites. The first, www.evorapro.com, is designed to educate dental professionals about the benefits of oral probiotics in maintaining good oral health and balance, while also providing information on becoming a partner with Oragenics and offering its professional strength product, EvoraPro, in their practices.
OGEN: 0.95 (unch)
Oragenics To Present Oral Care Probiotics Seminar at SupplySide MarketPlace 2013
Business Wire - Tue Apr 30, 8:33AM CDT
Oragenics, Inc. (NYSE:MKT: OGEN) today announced that Dr. Martin Handfield, Vice President of R&D for Oragenics, will be presenting a seminar entitled "Oral Care Probiotics Development" on Tuesday, April 30th at 5:00 pm at the SupplySide MarketPlace 2013, taking place from April 30 - May 2 at the Jacob Javits Center in New York, NY. SupplySide MarketPlace 2013 brings together the buyers and sellers that drive the dietary supplement, food, beverage, personal care, cosmetic and animal nutrition marketplaces. The Oragenics seminar is part of a practical short course entitled "Pre- & Probiotics Americas 2013: Pre- & Probiotics - Market, Science, Regulations and Applications" and will focus on describing the fundamental basis of oral probiotics, as well as highlighting the competitive advantage of the Oragenics line of oral care products.
OGEN: 0.95 (unch)
Clostridium Infections - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:16AM CDT
Research and Markets has announced the addition of the "Clostridium Infections - Pipeline Review, H1 2013" (http://www.researchandmarkets.com/research/p9lxmj/clostridium) report to their offering. 'Clostridium Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Infections. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Clostridium Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by u
EBS: 21.60 (+0.29), CBST: 72.42 (+3.27), MRK: 56.63 (+1.12), SRNE: 4.02 (+0.01), OGEN: 0.95 (unch), NVS: 89.24 (+1.04)
Oragenics Announces Approval of Common Stock Listing on NYSE MKT
Business Wire - Mon Apr 08, 9:11AM CDT
Oragenics, Inc. (OTCBB: OGEN) (the "Company"
announced today that its common stock has been approved for listing on the NYSE Euronext's NYSE MKT. Trading is expected to commence on the NYSE MKT on Wednesday, April 10, 2013 under the ticker symbol 'OGEN'. OGEN: 0.95 (unch)
Oragenics Receives First European Patent for ProBiora3(R) Probiotic Blend
Business Wire - Tue Mar 12, 8:23AM CDT
Oragenics, Inc. (OTCQB: OGEN)(OTCBB: OGEN) today announced it has received its first patent approval in Europe for its ProBiora3(R) products. The approval provides additional protection for ProBiora3's proprietary blend of three probiotic bacteria, specifically designed to enhance oral health, whiten teeth and freshen breath. ProBiora3 is currently being sold under the brand name Evora in the U.S. and in over 13 countries around the world.
OGEN: 0.95 (unch)
Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140
Business Wire - Tue Feb 12, 7:15AM CST
Oragenics, Inc. (OTCBB: OGEN) announced today that its Exclusive Channel Collaboration (ECC) with Intrexon Corporation, a synthetic biology company, has produced an exponential increase in the fermentation titer of the target compound MU1140 and the discovery of a promising new purification process for this product. This demonstrates significant progress toward the commercial production of its lead lantibiotic, MU1140, and delivers an important step in validating the lantibiotics platform targeting infectious diseases. Oragenics and Intrexon have been working together through the ECC to produce a pipeline of new lantibiotics that have been shown to be active against essentially all Gram-positive pathogens, including vancomycin-resistant enterococci (VRE), Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), as well as multi-drug resistant strains of Mycobacterium tuberculosis.
OGEN: 0.95 (unch)
Oragenics Receives European Union CPNP Notifications for ProBiora3(R) Cosmetic Tablets
Business Wire - Mon Feb 11, 8:00AM CST
Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN), today announced its ProBiora3(R) tablets intended to freshen breath, whiten teeth and contribute to overall oral health has successfully completed an independent third party review of its Cosmetic Product Safety Report. ProBiora3(R) is Oragenics' proprietary blend of probiotics specifically designed for oral care, and is now formulated as a cosmetic mouthwash tablet for use in the European Union. All Oragenics' independent distributors can now distribute the ProBiora3(R) tablets in the EU under a Cosmetic designation.
OGEN: 0.95 (unch)
Oragenics CEO To Present at The BIO CEO & Investor Conference on February 12th 2013
Business Wire - Mon Feb 11, 7:50AM CST
Oragenics, Inc. (OTCQB:OGEN) (OTCBB: OGEN), today announced Dr. John N. Bonfiglio, President and CEO of Oragenics, Inc., will present an overview of the company and an update on activities at the BIO CEO & Investor Conference in New York City on Tuesday, February 12th at 1:15 pm EST. The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies.
OGEN: 0.95 (unch)
Oragenics Inc signs new strategic partnership with Organic Wave Inc, getting access to Japanese pet market
M2 - Wed Jan 23, 10:20AM CST
Oral care probiotics company Oragenics Inc (OTC BB :OGEN) revealed on Tuesday the execution of a new strategic distribution agreement with Organic Wave Inc.
OGEN: 0.95 (unch)
Oragenics Announces New Strategic Partnership with Japanese-Based Company, Organic Wave, Inc. dba KYB America
Business Wire - Tue Jan 22, 7:15AM CST
Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN) (the "Company"
, a world leader in oral care probiotics, today announced that the Company has entered into a new three year contract agreement with Organic Wave, Inc. Under the terms of the agreement, Organic Wave will be the exclusive distributor of Oragenics' oral care probiotics for pets in Japan under the Evora name as well as a private label brand. The pet product will contain ProBiora3(R); Oragenics' patented proprietary blend of three probiotics specifically designed for improved oral health. OGEN: 0.95 (unch)
Oragenics CEO To Present at 6th Annual OneMedForum Investor Conference
Business Wire - Mon Jan 07, 7:15AM CST
Oragenics, Inc. (OTCQB:OGEN) (OTCBB:OGEN), today announced Dr. John Bonfiglio, President and CEO of Oragenics, Inc., will present an overview of the company at the 6th Annual OneMedForum in San Francisco on Tuesday, January 8th at 12:00 pm PST. Launched in 2008 by OneMedPlace, OneMedForum runs concurrently with the 31st Annual J.P. Morgan Healthcare Conference and brings together leading investors, strategic partners and management of some of the most promising emerging life science companies in Asia and North America.
JPM: 58.06 (+0.61), OGEN: 0.95 (unch)
